A novel, dual action chimera comprising DNA methylating agent and near-IR xanthene-cyanine photosensitizer for combined anticancer therapy

Ebaston Thankarajan, Dipak Walunj, Andrii Bazylevich, Chandrashekhar Prasad, Arkadi Hesin, Leonid Patsenker, Gary Gellerman

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

A facile synthesis, biological evaluation and photodynamic properties of novel activatable anticancer molecular hybrids (chimeras) Ch and I-Ch are described. The chimeras consist of DNA methylating methyl triazene moiety and fluorogenic xanthene-cyanine (XCy) or iodinated xanthene-cyanine (I-XCy) photosensitizer. These two anticancer core structures are bound by means of a self-immolative 4-aminobenzyl alcohol linker. The hydrolytic cleavage of the carbamate protecting group promotes activation of both DNA methylating monomethyl triazene and phototoxic xanthene-cyanine dye providing, in addition, a near-IR emission signal for detection of the drug activation events. Preliminary antiproliferative assay demonstrates that the developed chimeras exhibit higher antitumor activity in the breast cancer cell line upon near-IR light irradiation compared to their structural constituents, xanthene-cyanine photosensitizer and monomethyl triazene substance.

Original languageEnglish
Article number102722
JournalPhotodiagnosis and Photodynamic Therapy
Volume37
DOIs
StatePublished - Mar 2022

Keywords

  • Activatable anticancer prodrug
  • Activatable photosensitizer
  • Anticancer hybrid
  • DNA methylation
  • Fluorescence monitoring

Fingerprint

Dive into the research topics of 'A novel, dual action chimera comprising DNA methylating agent and near-IR xanthene-cyanine photosensitizer for combined anticancer therapy'. Together they form a unique fingerprint.

Cite this